Results 61 to 70 of about 3,679 (147)

PERPRISE: A prospective non‐interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic–clonic seizures: First interim analysis

Epilepsia Open
Objective To report the interim results of the PERPRISE study (Study 509; NCT04202159), which is evaluating perampanel as the only adjunctive anti‐seizure medication (ASM) in adults with focal to bilateral tonic–clonic seizures (FBTCS) or primary ...
Bernhard J Steinhoff, Tobias Goldmann, Edgar Kockelmann, Yaroslav Winter, for the PERPRISE Study Group   +4 more
doaj   +1 more source

Treatment Continuation and Long‐Term Outcomes of Perampanel in Primary Orthostatic Tremor; A Cohort Study

Movement Disorders Clinical Practice, EarlyView.
Background Primary orthostatic tremor (POT) is a rare hyperkinetic movement disorder with limited and largely ineffective treatment options. Perampanel has been suggested as a therapy, but has so far only been investigated in small studies with short duration.
Wietske A. Babeliowsky, Bart Swinnen, Jeroen Hoogland, Rob M.A. de Bie, Anne‐Fleur van Rootselaar   +4 more
wiley   +1 more source

Diagnostic Yield and Clinical Impact of Comprehensive WES/WGS Testing Beyond Common Genetic Causes in Hereditary Optic Atrophy

Clinical Genetics, EarlyView.
Opticus atrophy—Genetic testing with WES/WGS in 62 patients with optic atrophy provided a genetic diagnosis in 21 patients (33.9%). 42.9% of these involved non‐OPA1 genes, including WFS1, ACO2, NR2F1, UCHL1, CACNA1F, and COQ2, where the genetic diagnosis prompted additional clinical evaluation, surveillance, or therapeutic intervention.
Katrine M. Johannesen, Karen Grønskov, Line Kessel, Sarah Linea von Holstein, Lisbeth Birk Møller, Mette Kjøbæk Gundestrup Andersen, Marianne Søndergaard Khinchi, Steffen Hamann, Marianne Wegener, Mette Bertelsen   +9 more
wiley   +1 more source

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 1957-1976, July 2026.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, Elvira Bramon, Helen Cross, Natalie Curley, Sarah Curran, Helen Davies, Jana De Villiers, William Evans, Bernhard Frank, Alice Groves, Judith Hayward, Jon Higham, Dyfrig A. Hughes, Shwe Sin Kyaw, Anthony G. Marson, Ailsa McLellan, Seth Mensah, Francis O'Neill, Jane Sargison, Sanjay M. Sisodiya, Jill Swan, Joanna M. Zakrewska, Munir Pirmohamed   +24 more
wiley   +1 more source

Characterizing treatment initiation with central nervous system–active polypharmacy among adults with dementia

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Central nervous system (CNS) –active polypharmacy, defined as concurrent use of antidepressants, antipsychotics, anti‐seizure medications, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, opioids, or skeletal muscle relaxants for ≥ 31 consecutive days, poses significant risks patients with dementia.
Donovan T. Maust, Rachel C. Davis, Julie Strominger, Steven C. Marcus, Hyungjin Myra Kim, Tanner Caverly, Frederic C. Blow, Lauren P. Wallner, Sarah Krein, Sarah E. Vordenberg   +9 more
wiley   +1 more source

Severe Cutaneous Adverse Reactions Associated With Newer‐Generation Antiseizure Medications: A Real‐World Pharmacovigilance Study Based on FAERS and JADER

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
A cross‐database analysis of FAERS and JADER confirmed lamotrigine and zonisamide as the dominant SJS/TEN/DRESS risk drivers across both systems. After polytherapy adjustment, eslicarbazepine (DRESS, ROR 10.41) and levetiracetam emerged as reproducible novel signals warranting clinical attention. SJS/TEN onset concentrated within 4 weeks, whereas DRESS
Longfei You, Dong Zhang, Zhihua Cheng, Yinbao Qi, Ruobing Qian   +4 more
wiley   +1 more source

Perampanel as a second‐line therapy to midazolam reduces soman‐induced status epilepticus and neurodegeneration in rats

Epilepsia Open
Objective A benzodiazepine (diazepam or midazolam) is one of the current standards of care therapies to effectively terminate organophosphorus nerve agent‐induced status epilepticus when administered shortly after onset.
Hailey G. Steier, Caroline R. Schultz, Jerome Niquet, Donna A. Nguyen, Michael F. Stone, Abiel K. Biney, Marcio de Araujo Furtado, Claude G. Wasterlain, Lucille A. Lumley   +8 more
doaj   +1 more source

Perampanel: New drug for treatment of refractory partial onset seizures

Muller Journal of Medical Sciences and Research, 2014
Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest antiepileptic drugs for treatment of refractory partial onset seizures.
Santosh Kumar Singh, Dick B. S. Brashier
doaj   +1 more source

Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel

Epilepsy and Behavior Case Reports, 2014
Lafora disease is a rare and fatal disease characterized by seizures, progressive cognitive and behavioral deterioration, as well as cerebellar dysfunction.
Maya Dirani, Wassim Nasreddine, Fatima Abdulla, Ahmad Beydoun   +3 more
doaj   +1 more source

Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice

Epileptic Disorders, Volume 28, Issue 3, Page 775-785, June 2026.
Abstract Objective Patients with drug‐resistant epilepsy (DRE) typically take multiple anti‐seizure medications (ASMs) and are at risk of treatment‐related adverse events (AEs). This study assessed the impact of cenobamate monotherapy or dual therapy in patients with drug‐resistant epilepsy.
Álvaro Sánchez‐Guijo Benavente, Guillermina García Martín, Estuardo Daniel Castro Ruiz, Pablo Cabezudo García, Yolanda López Moreno, José Carlos Estévez María, Irene Lorite Fuentes, Sergio Navarro Conti, Raquel Calle Calle, Alejandro Fernández Cabrera, Isabel Ros González, Dulce Campos Blanco, María Isabel Chamorro Muñoz, Pedro Jesús Serrano Castro   +13 more
wiley   +1 more source